INmune Bio, Inc.
INMB
$1.98
-$0.03-1.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 257.14% | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 257.14% | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 257.14% | -100.00% | -- | -- |
| SG&A Expenses | -19.88% | -0.94% | -11.92% | -14.19% | 21.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.33% | -9.75% | 12.61% | 43.34% | 52.78% |
| Operating Income | 18.33% | 10.09% | -12.98% | -44.07% | -53.88% |
| Income Before Tax | -150.95% | 11.66% | -9.63% | -41.22% | -49.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.95% | 11.66% | -9.63% | -41.22% | -49.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.95% | 11.66% | -9.63% | -41.22% | -49.92% |
| EBIT | 18.33% | 10.09% | -12.98% | -44.07% | -53.88% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -107.96% | 29.22% | 11.17% | -25.99% | -39.33% |
| Normalized Basic EPS | 32.46% | 29.22% | 11.18% | -25.98% | -39.36% |
| EPS Diluted | -107.96% | 29.22% | 11.17% | -25.99% | -39.33% |
| Normalized Diluted EPS | 32.46% | 29.22% | 11.18% | -25.98% | -39.36% |
| Average Basic Shares Outstanding | 20.67% | 24.80% | 23.44% | 12.09% | 7.59% |
| Average Diluted Shares Outstanding | 20.67% | 24.80% | 23.44% | 12.09% | 7.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |